Overview

Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

Phase II, randomized, open-label study, designed to evaluate the preliminary efficacy and safety of tenalisib at two dose levels in 40 patients with locally advanced or metastatic breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Rhizen Pharmaceuticals SA

Treatments:

Tenalisib